BridgeBio Pharma, Inc. — Director's Dealing 2025

May 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-05-16

Reporting Person: Kumar Neil (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-16	Common Stock	M	64696	—	Acquired	276414	Direct
2025-05-16	Common Stock	F	32854	$33.84	Disposed	243560	Direct
2025-05-19	Common Stock	S	25756	$33.3229	Disposed	217804	Direct
2025-05-19	Common Stock	S	400	$33.7475	Disposed	217404	Direct
2025-05-20	Common Stock	S	75000	$33.3997	Disposed	4798447	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-16	Restricted Stock Units	$	M	33544	Disposed		Common Stock (33544)	Direct
2025-05-16	Restricted Stock Units	$	M	19599	Disposed		Common Stock (19599)	Direct
2025-05-16	Restricted Stock Units	$	M	11553	Disposed		Common Stock (11553)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	995686	Indirect

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,696 shares of Common Stock underlying the Reporting Person's RSUs.

F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F4: Represents the weighted average sale price of the shares sold from $32.72 to $33.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: Represents the weighted average sale price of the shares sold from $33.72 to $33.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F6: Represents the weighted average sale price of the shares sold from $33.02 to $33.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F7: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

F8: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F9: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F10: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.